GB202011125D0 - Use of cannabidiol in the treatment of seizures associated wiht rare epilepsy syndromes related to structural abnormalities of the brain - Google Patents
Use of cannabidiol in the treatment of seizures associated wiht rare epilepsy syndromes related to structural abnormalities of the brainInfo
- Publication number
- GB202011125D0 GB202011125D0 GBGB2011125.8A GB202011125A GB202011125D0 GB 202011125 D0 GB202011125 D0 GB 202011125D0 GB 202011125 A GB202011125 A GB 202011125A GB 202011125 D0 GB202011125 D0 GB 202011125D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- cannabidiol
- brain
- treatment
- structural abnormalities
- seizures associated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2011125.8A GB2597283A (en) | 2020-07-20 | 2020-07-20 | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| PCT/EP2021/069856 WO2022017929A1 (en) | 2020-07-20 | 2021-07-15 | Use of cannabidiol in the treatment of seizures associated lissencephaly |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2011125.8A GB2597283A (en) | 2020-07-20 | 2020-07-20 | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB202011125D0 true GB202011125D0 (en) | 2020-09-02 |
| GB2597283A GB2597283A (en) | 2022-01-26 |
Family
ID=72339052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2011125.8A Withdrawn GB2597283A (en) | 2020-07-20 | 2020-07-20 | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB2597283A (en) |
| WO (1) | WO2022017929A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2530001B (en) * | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2572737A (en) * | 2018-01-24 | 2019-10-16 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB201806953D0 (en) * | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| GB2584140A (en) * | 2019-05-23 | 2020-11-25 | Gw Res Ltd | Use of cannabidiol in the treatment of epileptic spasms |
-
2020
- 2020-07-20 GB GB2011125.8A patent/GB2597283A/en not_active Withdrawn
-
2021
- 2021-07-15 WO PCT/EP2021/069856 patent/WO2022017929A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022017929A1 (en) | 2022-01-27 |
| GB2597283A (en) | 2022-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202011120D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain | |
| GB202011155D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain | |
| GB202011123D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury | |
| GB202011175D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities | |
| GB202011178D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities | |
| GB202011174D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities | |
| GB202011168D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities | |
| GB202011166D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities | |
| GB202011161D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities | |
| GB202011160D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities | |
| GB202011159D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities | |
| GB202011156D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities | |
| GB202011164D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy sydromes related to genetic abnormalities | |
| GB202011171D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities | |
| GB202011127D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities | |
| GB202011169D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities | |
| GB202011153D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities | |
| GB202112440D0 (en) | Use of cannbidicarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities | |
| GB202019301D0 (en) | Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes | |
| GB202014723D0 (en) | Use of cannabinoids in the treatment of epilepsy | |
| GB202102010D0 (en) | Use of cannabidivarin in the treatment of seizures associated with canine epilepsy | |
| GB202011125D0 (en) | Use of cannabidiol in the treatment of seizures associated wiht rare epilepsy syndromes related to structural abnormalities of the brain | |
| GB202110388D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain | |
| GB202011146D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain | |
| GB202011141D0 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |